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Background
This interesting case highlights the clinical progression of a rare 
disease process and the important role of a multi-disciplinary 
team in achieving a diagnosis and successful management plan.
Case Presentation
A 76-year-old male with a history of coronary artery disease, 
hypertension and hyperlipidemia presented as an outpatient 
with left foot pain and swelling. He had spent a week bicycling 
in Colorado one month prior to presentation. The pain was 
initially localized to the plantar surface of his foot and progressed 
to involve the lateral and dorsal aspects of the foot, as well as his 
great toe. The pain was accompanied by swelling of the midfoot 
without erythema and he was unable to bear weight. His podiatrist 
prescribed Ibuprofen and a foot brace for empiric treatment of 
tendonitis. An outpatient MRI demonstrated extensive bony 
edema and synovial enhancement within the midfoot, as well 
as severe superficial edema and peroneal tendonitis with mild 
subluxation. The patient was sent to the emergency department 
to be evaluated for osteomyelitis.
On exam, the patient was afebrile with normal vital signs. The 
left foot was warm and edematous without erythema or discrete 
fluid collection. There were no ulcers or breaks in the skin. The 
dorsal portion of the foot was exquisitely tender to palpation. The 
ankle had decreased active and passive range of motion. Pedal 
pulses were equal, and sensation was intact. Initial chemistries 
were significant for an erythrocyte sedimentation rate (ESR) of 
81 mm/hr and C reactive protein (CRP) of 1.1 mg/dL. Foot and 
ankle x-rays were negative for fracture or dislocation. Venous 
ultrasound of the lower extremities was negative for deep venous 
thrombosis.
The patient was evaluated by orthopedic surgery and was 
diagnosed with severe bony stress and trauma from his prolonged 
bike trip. A full rheumatologic evaluation was normal. A fluid 
collection amenable to arthrocentesis was not identifiable. Based 
on imaging and physical exam, the Infectious Disease team did 
not feel there was evidence of osteomyelitis. The patient was 
prescribed high-dose Ibuprofen to treat inflammation caused 
by bony trauma and placed in an air boot. The patient’s pain and 
edema improved and he was discharged.
Two weeks later, the patient presented with worsening left foot 
pain, edema, and continued inability to bear weight. He was 
noted to have new left calf atrophy, but proximal and distal 
muscles of the legs had full strength. Laboratory results were 
significant for a leukocytosis of 11.7 B/L, CRP of 2.2 mg/dL, and 
ESR of 94 mm/hr. A left foot x-ray demonstrated progression 
of left foot swelling, osteoporosis, and intertarsal joint erosions. 
An MRI of the lumbosacral spine to evaluate for nerve root 
compression did not identify any mass or abnormal signal 
along the lumbosacral plexus. An MRI of the left foot and ankle 
demonstrated unchanged bone marrow edema. No drainable 
fluid collection was identified, and there was no evidence of 
osteomyelitis. A bone scan demonstrated abnormal activity 
within the left midfoot consistent with neuropathic joint disease 
and synovitis of the left knee. Orthopedic surgery was consulted, 
and additionally diagnosed micro-fractures of the midfoot, 
visible on the left foot x-ray and MRI. Their diagnosis was 
neuropathic joint disease and they recommended non-weight-
bearing status for joint preservation. 
The patient developed progressive left knee edema and posterior 
tenderness to palpation. An ultrasound of the left leg and ankle 
demonstrated a Baker cyst, as well as chondrocalcinosis in 
the cartilage of the talar dome and extensive synovitis of the 
talonavicular and tarsometatarsal joints (Figures 1,2). Results 
were discussed with Neurology and Radiology and a diagnosis 
of pseudogout of the left knee, foot and ankle was made. 
Rheumatology recommended high dose scheduled Naproxen. 
The patient’s pain and edema improved, and he was discharged 
home with Naproxen and an orthopedic boot.
Outcome and Follow-up
Two weeks after discharge, rheumatology aspirated three 
milliliters of straw-colored fluid from the left ankle, which 
contained calcium pyrophosphate crystals, consistent with 
pseudogout. An ultrasound four months later demonstrated 
improvement in the left talonavicular and tarsometatarsal joint 
synovitis, and a small tibiotalar joint effusion with persistent 
chondrocalcinosis. The patient’s outpatient orthopedic surgeon 
confirmed the diagnosis of pseudogout, with associated pseudo-
neuropathic joint disease. The patient is currently being 
maintained on low dose scheduled Naproxen and Methotrexate 
as an outpatient. He is no longer wearing an orthopedic boot, 
and is progressively regaining his mobility.
Discussion
This case highlights the importance of an evolving differential 
diagnosis, based on physical exam, laboratory and radiological 
tests. The initial outpatient differential diagnosis included severe 
multifocal stress response, osteomyelitis, and early neuropathic 
change, and evolved to include reflex sympathetic dystrophy, 
osteoporosis and finally pseudogout with associated neuropathic 
joint disease. 
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Calcium pyrophosphate dehydrate (CPPD) crystal deposition, 
and ensuing crystal-induced synovitis, is an important pathologic 
entity that is part of a spectrum of disease. This includes 
pseudogout, or acute attacks of CPPD synovitis, chondrocal-
cinosis, or radiographically evident deposition of CPPD crystals, 
and CPPD arthropathy, or chronic joint disease that typically 
accompanies CPPD crystal deposition. This disease process 
has important epidemiologic implications, as estimates suggest 
an age-related rise in prevalence of related chondrocalcinosis.1 
CPPD crystal formation is thought to initiate near the surface 
of chondrocytes and may be related to purely elevated levels 
of calcium, pyrophosphate, or local cartilage matrix changes 
that enhance calcium or pyrophosphate levels. Most cases are 
idiopathic, but some are associated with an underlying disorder. 
Hemochromatosis, hyperparathyroidism, hypophosphatemia, 
hypomagnesemia, familial hypocalciuric hypercalcemia, 
Gitelman’s syndrome, gout, and hypothyroidism have been 
shown to be associated with CPPD. Joint trauma or joint instru-
mentation is also an important etiology.2,3 
Definitive diagnosis of CPPD crystal deposition disease is 
made by synovial fluid analysis. Microscopy of aspirated fluid 
will demonstrate the presence of positively birefringent CPPD 
crystals. CPPD crystal deposits can be imaged by plain film 
radiography as linear radiodensities in joint cartilage, ligaments 
and joint capsules.4 Ultrasound imaging can also be used to 
diagnose CPPD deposition disease. CPPD crystals will appear as 
hyperechoic bands along the cartilage surface or as hyperechoic 
spots in the fibrocartilage.5
There are few cases of CPPD crystal deposition disease associated 
with severe joint degeneration resembling neuropathic 
arthropathy and Charcot joint. This rare condition that has 
been termed “pseudo-neuropathic joint disease.” It has been 
speculated that acute episodes of pseudogout and chondrocal-
cinosis can precede the development of Charcot arthropathy 
through cartilaginous microfractures, which results in the 
shedding of CPPD crystals into the joint cavity and progressive 
joint destruction.6-8
In patients with acute CPPD crystal arthritis, the CPPD crystals 
should be removed by arthrocentesis. Intra-articular injection of 
glucocorticoids is recommended in patients with no more than 
two involved joints. When more than two joints are involved, 
administration of oral non-steroidal anti-inflammatory (NSAID) 
medications is recommended. For patients in whom NSAIDs 
are contraindicated, colchicine can be used, and in patients for 
whom NSAIDs and colchicine are contraindicated, systemic 
glucocorticoids or immunomodulators such as methotrexate 
can be used. Joint immobilization is the mainstay of therapy 
for pseudo-neuropathic joint disease in order to prevent the 
development of microfractures and joint collapse.9
Key Points
Pseudo-neuropathic pseudogout is a rare disease process that 
can be difficult to elucidate. The key to diagnosis is arthro-
centesis of the involved joint and the identification of calcium 
pyrophosphate crystals in the synovial fluid. Ultrasound is a 
Figure 1. Color Doppler Ultrasound, sagittal view of 
the talonavicular joint, showing thickened synovium 
and increased color Doppler flow, indicating synovitis.
Figure 2. Ultrasound, sagittal view through the tibiotalar joint, showing 
cartilage calcification (arrow) at the talar dome, diagnostic of chondrocalcinosis
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sensitive and specific technique for identifying chondrocal-
cinosis in a patient with suspected neuropathic joint disease. 
The mainstay of treatment is NSAID therapy.
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